Oncology Treatment Evolution and Upcoming Launches
•
3 j'aime•833 vues
A compelling infographic from the latest issue of AccessPoint demonstrating what is in the oncology pipeline, both in development and launch phases.
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (20)
En vedette
En vedette (9)
Similaire à Oncology Treatment Evolution and Upcoming Launches
Similaire à Oncology Treatment Evolution and Upcoming Launches (20)
Plus de IMSHealthRWES
Plus de IMSHealthRWES (18)
Dernier
Dernier (20)
Oncology Treatment Evolution and Upcoming Launches
- 1. PAGE 2 IMS HEALTH REAL-WORLD EVIDENCE SOLUTIONS INSIGHTS HOW IS ONCOLOGY TREATMENT EVOLVING? ACCESSPOINT • VOLUME 6 • ISSUE 12 PAGE 3 20172016 2018 2019 2020 >2020 The Current Oncology Pipeline: Development & Launch Exceptional launch activity increases options for patients but requires a greater understanding of treatment pathways and patient segments for payers and clinicians. The sheer volume of potential new products drives a need to reassess the way information about these expanded options is conveyed to stakeholders. These figures are estimates based on phase III completion dates. The actual number of launches will depend on successful trial completion and FDA approval. Products in phase II that could successfully move through launch are not included. Intense R&D activity reflects tremendous market growth and an increased understanding of oncology. Of the 100+ molecules in phase III development, 68% are targeted agents, illustrating how oncology will become even more specialized. Breast Cancer Non-Small Cell Lung Cancer 80% 10% 10% Ovarian Cancer Acute Myeloid Leukemia Gastric Cancer 8% 46% 23% 23% 66% 17% 17% 66% 17% 17% 80% 20% 50% 50% Hepatocellular Carcinoma Melanoma 38% 49% 7% 3% 3% 75% 25% 68% 26% 100% Colorectal Cancer 61% 13% 13% 13% Renal Cell Cancer Non-Hodgkin Lymphoma Others 4 66 5 4 19 19 13 8 4 29 6% 57% 11% 26% 2% 2% 2% 11 33 12% 73%3%12% 58 53% 34% 13% 54% 42% 4% 61% 35% 4% 47 24 23 73% 18% 9% 70%20% 10% 47% 53% 83%17%58% 14% 14% 14% 41% 3% 56% 39 10 7 6 2986%7% 7% 20% 15 Launch activity over the next 4 years promises a range of new options across solid and hematological malignancies Note: Represents the top 10 tumors by number of launches from 2016-2020 Number of Launches Acute Myeloid Leukemia 47%33% 15 Gastric Cancer 20% Hepato- cellular Carcinoma MelanomaBreast Cancer 80% 10% 10% 10 Ovarian Cancer Colorectal Cancer 100% 8 Chronic Lymphocytic Leukemia 100% 10 Non-Hodgkin Lymphoma Non-Small Cell Lung Cancer Source all data: IMS R&D Focus; www.clinicaltrials.gov Vaccine Targeted Oncolytic Virus Immuno-oncology Others Chemotherapy Activity Breakdown Unprecedented launches signal new needs for stakeholder engagement 68% 2% 7% 18% VaccineImmuno-oncologyTargeted Chemotherapy Oncolytic Virus Other n=101 Saurabh Kumar, MD, MBA – Senior Manager, Global Delivery Center, IMS Health, Skumar1@in.imshealth.com Divya Dhingra, MSC – Associate Consultant, IMS Health, Ddhingra@in.imshealth.com 2016 2018 2019 2020 >20202017 3% 2% Total Clinical Activity 18%